KemPharm, Inc. (KMPH) Given Consensus Rating of “Buy” by Brokerages
Shares of KemPharm, Inc. (NASDAQ:KMPH) have received an average rating of “Buy” from the six ratings firms that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have issued a buy recommendation on the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $9.00.
KMPH has been the topic of a number of recent research reports. Zacks Investment Research downgraded shares of KemPharm from a “hold” rating to a “sell” rating in a report on Tuesday, May 16th. Roth Capital initiated coverage on shares of KemPharm in a report on Wednesday, June 28th. They issued a “buy” rating and a $8.00 price objective on the stock. ValuEngine upgraded shares of KemPharm from a “strong sell” rating to a “sell” rating in a report on Saturday, July 1st. Oppenheimer Holdings, Inc. set a $13.00 price objective on shares of KemPharm and gave the company a “buy” rating in a report on Wednesday, May 10th. Finally, Royal Bank Of Canada reiterated a “buy” rating and issued a $8.00 price objective on shares of KemPharm in a report on Monday, May 15th.
TRADEMARK VIOLATION NOTICE: This piece was first posted by American Banking News and is owned by of American Banking News. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of US & international copyright laws. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/08/22/kempharm-inc-kmph-given-consensus-rating-of-buy-by-brokerages.html.
KemPharm (NASDAQ:KMPH) opened at 2.90 on Tuesday. The firm’s market cap is $42.51 million. KemPharm has a 52 week low of $2.45 and a 52 week high of $5.47. The stock’s 50 day moving average is $3.35 and its 200 day moving average is $3.90.
KemPharm (NASDAQ:KMPH) last posted its quarterly earnings data on Thursday, August 10th. The specialty pharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.63) by $0.19. Equities research analysts expect that KemPharm will post ($2.72) EPS for the current year.
In other news, CEO Travis C. Mickle bought 8,000 shares of the stock in a transaction that occurred on Tuesday, June 20th. The shares were acquired at an average cost of $3.45 per share, for a total transaction of $27,600.00. Following the completion of the acquisition, the chief executive officer now owns 1,629,612 shares in the company, valued at $5,622,161.40. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Over the last 90 days, insiders have purchased 10,775 shares of company stock worth $38,783. 22.80% of the stock is owned by corporate insiders.
Institutional investors have recently modified their holdings of the company. C WorldWide Group Holding A S increased its position in shares of KemPharm by 110.1% in the second quarter. C WorldWide Group Holding A S now owns 381,699 shares of the specialty pharmaceutical company’s stock worth $1,527,000 after buying an additional 200,000 shares during the last quarter. Victory Capital Management Inc. purchased a new position in shares of KemPharm during the first quarter worth $647,000. Finally, Bank of New York Mellon Corp increased its position in shares of KemPharm by 17.6% in the first quarter. Bank of New York Mellon Corp now owns 22,854 shares of the specialty pharmaceutical company’s stock worth $112,000 after buying an additional 3,414 shares during the last quarter. Institutional investors and hedge funds own 43.60% of the company’s stock.
KemPharm Company Profile
KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).
Receive News & Ratings for KemPharm Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm Inc. and related companies with MarketBeat.com's FREE daily email newsletter.